Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
- PMID: 25351522
- PMCID: PMC4341911
- DOI: 10.1136/annrheumdis-2014-205675
Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
Abstract
Objectives: We aimed to quantify the risk of major adverse cardiovascular events (MACE) among patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA) and psoriasis without known PsA compared with the general population after adjusting for traditional cardiovascular risk factors.
Methods: A population-based longitudinal cohort study from 1994 to 2010 was performed in The Health Improvement Network (THIN), a primary care medical record database in the UK. Patients aged 18-89 years of age with PsA, RA or psoriasis were included. Up to 10 unexposed controls matched on practice and index date were selected for each patient with PsA. Outcomes included cardiovascular death, myocardial infarction, cerebrovascular accidents and the composite outcome (MACE). Cox proportional hazards models were used to calculate the HRs for each outcome adjusted for traditional risk factors. A priori, we hypothesised an interaction between disease status and disease-modifying antirheumatic drug (DMARD) use.
Results: Patients with PsA (N=8706), RA (N=41 752), psoriasis (N=138 424) and unexposed controls (N=81 573) were identified. After adjustment for traditional risk factors, the risk of MACE was higher in patients with PsA not prescribed a DMARD (HR 1.24, 95% CI 1.03 to 1.49), patients with RA (No DMARD: HR 1.39, 95% CI 1.28 to 1.50, DMARD: HR 1.58, 95% CI 1.46 to 1.70), patients with psoriasis not prescribed a DMARD (HR 1.08, 95% CI 1.02 to 1.15) and patients with severe psoriasis (DMARD users: HR 1.42, 95% CI 1.17 to 1.73).
Conclusions: Cardiovascular risk should be addressed with all patients affected by psoriasis, PsA or RA.
Keywords: Epidemiology; Outcomes research; Psoriatic Arthritis; Rheumatoid Arthritis.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Figures
Comment in
-
Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation?Ann Rheum Dis. 2015 Feb;74(2):321-2. doi: 10.1136/annrheumdis-2014-206617. Epub 2014 Nov 26. Ann Rheum Dis. 2015. PMID: 25429028 No abstract available.
-
Heart of the matter.Cutis. 2019 Aug;104(2S):6. Cutis. 2019. PMID: 31634383 No abstract available.
Similar articles
-
Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study.Ann Rheum Dis. 2014 Jan;73(1):149-53. doi: 10.1136/annrheumdis-2012-202424. Epub 2012 Dec 21. Ann Rheum Dis. 2014. PMID: 23264338 Free PMC article.
-
Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study.Eur Heart J. 2018 Oct 14;39(39):3608-3614. doi: 10.1093/eurheartj/ehx145. Eur Heart J. 2018. PMID: 28444172 Free PMC article.
-
Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.Arthritis Care Res (Hoboken). 2019 Apr;71(4):512-520. doi: 10.1002/acr.23609. Arthritis Care Res (Hoboken). 2019. PMID: 29799667 Free PMC article.
-
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5. Ann Rheum Dis. 2015. PMID: 25561362 Free PMC article. Review.
-
Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.Curr Pharm Des. 2014;20(4):500-12. doi: 10.2174/138161282004140213123505. Curr Pharm Des. 2014. PMID: 23565631 Review.
Cited by
-
Metabolic Syndrome in Psoriasis and Psoriatic Arthritis in a Mixed Race Population: Comparison of Their Prevalences.Psoriasis (Auckl). 2024 Oct 31;14:123-130. doi: 10.2147/PTT.S471707. eCollection 2024. Psoriasis (Auckl). 2024. PMID: 39498380 Free PMC article.
-
Exploration of Risk Factors for Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Retrospective Study.Inflammation. 2024 Oct 16. doi: 10.1007/s10753-024-02157-5. Online ahead of print. Inflammation. 2024. PMID: 39414673
-
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status.Rheumatol Ther. 2024 Dec;11(6):1649-1664. doi: 10.1007/s40744-024-00711-z. Epub 2024 Sep 25. Rheumatol Ther. 2024. PMID: 39320582 Free PMC article.
-
Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis.JAMA Cardiol. 2024 Nov 1;9(11):1009-1017. doi: 10.1001/jamacardio.2024.2859. JAMA Cardiol. 2024. PMID: 39292496 Free PMC article.
-
The Association Between Psoriasis and Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis of Observational Studies.Cureus. 2024 Jun 28;16(6):e63379. doi: 10.7759/cureus.63379. eCollection 2024 Jun. Cureus. 2024. PMID: 38947134 Free PMC article. Review.
References
-
- Koolaee RM, Takeshita J, Ogdie A. Epidemiology and Natural History of Psoriatic Arthritis: An Update. Curr Derm Rep. 2013;2:66–76.
-
- Jamnitski A, Symmons D, Peters MJL, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211–216. - PubMed
-
- Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68:1131–1135. - PubMed
-
- Ahlehoff O, Gislason G, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147–157. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K24AR064310/AR/NIAMS NIH HHS/United States
- R01AG025152/AG/NIA NIH HHS/United States
- K23AR063764/AR/NIAMS NIH HHS/United States
- 8UL1TR000003/TR/NCATS NIH HHS/United States
- UL1 TR000003/TR/NCATS NIH HHS/United States
- K23 AR063764/AR/NIAMS NIH HHS/United States
- K23HL097151-01/HL/NHLBI NIH HHS/United States
- R01 AG025152/AG/NIA NIH HHS/United States
- L30 AR060070/AR/NIAMS NIH HHS/United States
- R01HL089744/HL/NHLBI NIH HHS/United States
- R01 HL089744/HL/NHLBI NIH HHS/United States
- K23 HL097151/HL/NHLBI NIH HHS/United States
- K24 AR064310/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous